Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
Public ClinicalTrials.gov record NCT03229278. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Study to Evaluate the Safety of Trigriluzole (FC-4157/BHV-4157) in Combination With PD-1 Blocking Antibodies
Study identification
- NCT ID
- NCT03229278
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Enrollment
- 14 participants
Conditions and interventions
Conditions
- Lymphoma
- Metastatic Malignant Solid Neoplasm
- Metastatic Melanoma
- Metastatic Renal Cell Cancer
- Recurrent Bladder Carcinoma
- Recurrent Classical Hodgkin Lymphoma
- Recurrent Head and Neck Squamous Cell Carcinoma
- Recurrent Lymphoma
- Recurrent Malignant Solid Neoplasm
- Recurrent Renal Cell Carcinoma
- Stage III Bladder Cancer
- Stage III Lymphoma
- Stage III Non-Small Cell Lung Cancer AJCC v7
- Stage III Renal Cell Cancer
- Stage III Skin Melanoma
- Stage IIIA Non-Small Cell Lung Cancer AJCC v7
- Stage IIIA Skin Melanoma
- Stage IIIB Non-Small Cell Lung Cancer AJCC v7
- Stage IIIB Skin Melanoma
- Stage IIIC Skin Melanoma
- Stage IV Bladder Cancer
- Stage IV Lymphoma
- Stage IV Non-Small Cell Lung Cancer AJCC v7
- Stage IV Renal Cell Cancer
- Stage IV Skin Melanoma
- Stage IVA Bladder Cancer
- Stage IVB Bladder Cancer
- Unresectable Head and Neck Squamous Cell Carcinoma
- Unresectable Solid Neoplasm
Interventions
- Enzyme Inhibitor Therapy Drug
- Laboratory Biomarker Analysis Other
- Nivolumab Biological
- Pembrolizumab Biological
Drug · Other · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2, 2017
- Primary completion
- Oct 19, 2022
- Completion
- Oct 29, 2022
- Last update posted
- Dec 5, 2023
2017 – 2022
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08903 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03229278, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 5, 2023 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03229278 live on ClinicalTrials.gov.